C
Cardiac Dimensions
Medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation
About Cardiac Dimensions
Cardiac Dimensions is a medical device company that has developed a minimally invasive treatment for heart failure and related cardiovascular conditions. The company's flagship product is the Carillon Mitral Contour System, a device designed to treat functional mitral regurgitation (FMR), a condition in which the mitral valve fails to close properly, causing blood to leak backward into the left atrium.
Read full description
The Carillon system is a right-sided, non-surgical therapy that offers a simple and safe approach to treating FMR. The device is implanted in the coronary sinus, a large vein that wraps around the heart, and reshapes the mitral annulus, the ring of tissue that supports the mitral valve. This reshaping helps to improve the valve's function and reduce the amount of blood that leaks backward.
The company's business model is focused on the development and commercialization of the Carillon system. Cardiac Dimensions generates revenue through the sale of the device to hospitals and other healthcare providers. The company's target market includes patients with FMR who are not candidates for open-heart surgery or other more invasive treatments.
At a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Kirkland, United States
- Employees
- 72
- Open positions
- 1
- Dealroom signal
- 83.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Intellectual Property, Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Mar 2025 | $53M | $212M | Horizon 3 Healthcare · Ally Bridge Group · Hostplus · M. H. Carnegie & | ↗ |
| SERIES DOther financing | Jan 2023 | $35M | $140M | Hostplus · M. H. Carnegie & · EQT Group · Arboretum Ventures | ↗ |
Growth signals
Latest recorded traffic for Cardiac Dimensions is 1.1K monthly website visits, down 50% over the last three months. Cardiac Dimensions's team grew 2.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
REDBUS GROUP LIMITED
Lumira Ventures
Series A5 investors entered at this stage
Polaris Partners
InterWest Partners
MPM BioImpact
Hostplus
Oxford Finance
Series B and later13 investors entered at this stage
Frazier Healthcare Partners
The Seattle Times
Johnson & Johnson Development Corporation
EQT Life Sciences- APAperture Venture Partners
Arboretum Ventures
Difference Capital
M. H. Carnegie &
EQT Group- H3Horizon 3
Ally Bridge Group
Horizon 3 Healthcare
Claret Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cardiac Dimensions on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cardiac Dimensions’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.